Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Non-Hodgkin Lymphoma
100%
Lymphoma
50%
Cellular Products
50%
Median Survival
25%
T Cells
25%
Tumor Cells
25%
Adoptive Transfer
25%
U.S. Food
25%
Major Contributor
25%
Clinical Response
25%
Clinical Efficacy
25%
Chemotherapy Resistance
25%
Killing Activity
25%
Treatment Refractory
25%
T Cell Immunotherapy
25%
B-cell non-Hodgkin Lymphoma (B-NHL)
25%
CD19
25%
Product-specific
25%
Laboratory Bench
25%
Dismal Prognosis
25%
Refractory Lymphoma
25%
Line of Therapy
25%
Genetic Engineering Technology
25%
Conventional Lines
25%
Medicine and Dentistry
Chimeric Antigen Receptor T-Cell
100%
Patient with Non-Hodgkins Lymphoma
100%
Immunotherapy
66%
T Cell
66%
Genetic Engineering
33%
Tumor Cell
33%
B Cell
33%
Chimeric Antigen Receptor
33%
Adoptive Transfer
33%
Non-Hodgkin Lymphoma
33%
Cell Antigen
33%
CD19 Antigen
33%
Immunology and Microbiology
Chimeric Antigen Receptor T-Cell
100%
T Cell
66%
Immunotherapy
66%
B Cell
33%
Chimeric Antigen Receptor
33%
Tumor Cell
33%
Cell Antigen
33%
CD19 Antigen
33%
Genetic Engineering
33%